Oseni is a medicine prescribed to treat type 2 diabetes. It works by decreasing the amount of sugar made by the liver and increasing the amount of insulin produced in response to meals. Side effects are possible and may include back pain, a sore throat, and upper respiratory tract infections. This medication comes as a tablet that is taken once daily.
Oseni® (alogliptin and pioglitazone) is a prescription medication approved to treat adults with type 2 diabetes. It is used in conjunction with an appropriate diet and exercise to improve blood glucose (blood sugar) control. Oseni contains a combination of two diabetes medications: alogliptin (Nesina®) and pioglitazone (Actos®).
Oseni will not work to treat type 1 diabetes or diabetic ketoacidosis, a potentially life-threatening problem that can occur in people with diabetes. It should not be used in people with these conditions.
Oseni is made by Takeda Pharmaceuticals America, Inc.
Oseni itself has not been studied in clinical trials. However, the combination of alogliptin and pioglitazone (the two active ingredients in Oseni) has been studied in people with type 2 diabetes that was not already well controlled with diet and exercise or with another diabetes medication (metformin [Glucophage®]). In these studies, people given the combination of alogliptin and pioglitazone had a reduction in their hemoglobin A1c (HbA1c) and fasting blood glucose.
Effects on Hemoglobin A1c
Hemoglobin A1c (HbA1c) is a test used to measure long-term blood sugar control. People without diabetes and those with well-controlled diabetes usually have HbA1c results that are less than 6 percent. Studies have shown that the higher the HbA1c, the greater the chance for developing long-term problems related to diabetes, such as heart, eye, nerve, and kidney problems.
In one study, people taking alogliptin with pioglitazone for 26 weeks lowered their HbA1c by 1.7 percent, on average. In comparison, people taking alogliptin alone lowered their HbA1c by 1 percent, and people taking pioglitazone alone lowered their HbA1c by 1.2 percent.
Effects on Blood Sugar Levels
In the same study, people given the combination of pioglitazone and alogliptin had a lowering of their fasting blood sugar by 50 mg/dL, on average. In comparison, pioglitazone alone lowered fasting blood glucose by 37 mg/dL, on average, and alogliptin alone by 26 mg/dL, on average.